Q3 2025 · 13F-HR
Logos Global Management LPholdings as filed
Filed 2025-11-14 · accession 0001172661-25-004983
$1.12B
Reported value
59
Positions
2025-09-30
Period end
The Brief · Logos Global Management LP · Q3 2025
AI · grounded in 13F
Logos Global Management LP established a new position in Revolution Medicines Inc RVMD valued at $128.4M. The fund also initiated new stakes in Ideaya Biosciences Inc IDYA for $73.5M and Akero Therapeutics Inc AKRO for $57M. These moves contributed to a portfolio of 56 positions with total assets under management of $1.1B.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $81.7M | 7.33% | 1,750,000 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $61.2M | 5.49% | 2,250,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $57.0M | 5.11% | 1,200,000 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $47.5M | 4.26% | 5,575,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $46.7M | 4.19% | 1,000,000 | CALL | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $38.0M | 3.41% | 3,250,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $35.9M | 3.22% | 375,000 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $35.8M | 3.21% | 4,050,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $35.2M | 3.16% | 415,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $33.0M | 2.96% | 15,150,000 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $31.8M | 2.85% | 1,227,300 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $31.4M | 2.82% | 3,208,875 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $30.9M | 2.77% | 850,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $30.4M | 2.72% | 2,400,000 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $29.7M | 2.67% | 450,000 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $27.5M | 2.47% | 3,655,000 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $26.4M | 2.36% | 200,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $26.1M | 2.34% | 600,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $23.8M | 2.13% | 850,000 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $22.9M | 2.05% | 935,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $22.6M | 2.03% | 1,000,000 | CALL | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $22.5M | 2.02% | 625,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $20.2M | 1.81% | 200,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $20.1M | 1.80% | 2,200,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $19.9M | 1.79% | 300,000 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $19.7M | 1.77% | 1,450,000 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $17.8M | 1.60% | 1,130,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $17.5M | 1.57% | 300,000 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $14.2M | 1.27% | 250,000 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $14.0M | 1.26% | 100,000 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $13.5M | 1.21% | 165,000 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $13.4M | 1.21% | 850,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $12.7M | 1.14% | 525,000 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $12.2M | 1.10% | 450,000 | CALL | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $12.2M | 1.10% | 500,000 | CALL | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $8.1M | 0.72% | 2,500,000 | CALL | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $8.0M | 0.72% | 950,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $7.9M | 0.71% | 200,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $7.2M | 0.64% | 500,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $7.2M | 0.64% | 2,050,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $7.1M | 0.64% | 600,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $7.0M | 0.62% | 340,000 | Common | SOLE |
| 45254E107 | IMRX | IMMUNEERING CORP | $6.7M | 0.60% | 950,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $6.6M | 0.59% | 125,000 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $6.5M | 0.58% | 175,000 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $5.4M | 0.48% | 625,000 | Common | SOLE |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $5.3M | 0.48% | 900,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $4.4M | 0.40% | 275,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $3.7M | 0.34% | 150,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $3.6M | 0.33% | 500,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $3.5M | 0.31% | 750,000 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $2.9M | 0.26% | 1,500,000 | Common | SOLE |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $2.1M | 0.19% | 473,563 | Common | SOLE |
| 29664W105 | ESPR | ESPERION THERAPEUTICS INC NE | $2.0M | 0.18% | 750,000 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $1.6M | 0.14% | 83,548 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $1.5M | 0.13% | 500,000 | CALL | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $1.0M | 0.09% | 500,000 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $795,000 | 0.07% | 500,000 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $13,473 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.